FGFR-2 beta (IIIb) Protein, Human (HEK293, His)

The FGFR-2 α IIIc protein is a tyrosine protein kinase receptor for fibroblast growth factor and is critical for embryonic development, regulating proliferation, differentiation, and apoptosis. Its importance is evident in embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis, and skin development. FGFR-2 beta (IIIb) Protein, Human (HEK293, His) is the recombinant human-derived FGFR-2 beta IIIb protein, expressed by HEK293 , with C-6*His labeled tag.

FGFR-2 alpha IIIc protein, a tyrosine-protein kinase, serves as a cell-surface receptor for fibroblast growth factors and holds a pivotal role in regulating cell proliferation, differentiation, migration, and apoptosis, as well as embryonic development. Its indispensability is evident in normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis, and skin development. Moreover, FGFR-2 alpha IIIc plays a crucial role in osteoblast differentiation, proliferation, and apoptosis, contributing significantly to normal skeleton development. While promoting cell proliferation in keratinocytes and immature osteoblasts, it fosters apoptosis in differentiated osteoblasts. Upon ligand binding, FGFR-2 alpha IIIc activates multiple signaling cascades, including the phosphorylation of PLCG1, FRS2, and PAK4. Activation of PLCG1 triggers the production of cellular signaling molecules such as diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 leads to the recruitment of GRB2, GAB1, PIK3R1, and SOS1, mediating the activation of RAS, MAPK1/ERK2, MAPK3/ERK1, the MAP kinase signaling pathway, and the AKT1 signaling pathway. To regulate FGFR2 signaling, the protein undergoes down-regulation through ubiquitination, internalization, and degradation. Mutations resulting in constitutive kinase activation or impairing normal FGFR2 maturation, internalization, and degradation lead to aberrant signaling. Additionally, overexpressed FGFR2 promotes the activation of STAT1.

The enzyme activity of this recombinant protein is testing in progress, we cannot offer a guarantee yet.

Human

HEK293

C-6*His

P21802-3 (R152-E378)

2263  [NCBI]

Partial

RAPYWTNTEKMEKRLHAVPAANTVKFRCPAGGNPMPTMRWLKNGKEFKQEHRIGGYKVRNQHWSLIMESVVPSDKGNYTCVVENEYGSINHTYHLDVVERSPHRPILQAGLPANASTVVGGDVEFVCKVYSDAQPHIQWIKHVEKNGSKYGPDGLPYLKVLKHSGINSSNAEVLALFNVTEADAGEYICKVSNYIGQANQSAWLTVLPKQQAPGREKEITASPDYLE

Approximately 40-70 kDa,based on SDS-PAGE under reducing conditions.

≥ 95%, as determined by reducing SDS-PAGE.

Lyophilized powder

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.